These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36951032)

  • 41. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
    Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
    Chernov AN; Filatenkova TA; Glushakov RI; Buntovskaya AS; Alaverdian DA; Tsapieva AN; Kim AV; Fedorov EV; Skliar SS; Matsko MV; Galimova ES; Shamova OV
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 44. [Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
    Shi L; Li H; Gu J; Song C; Li J; Chen L; Zhou Q; Qi S; Lu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):69-74. PubMed ID: 33509755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
    Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
    J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
    [TBL] [Abstract][Full Text] [Related]  

  • 46. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
    Wang N; Zhang Q; Ning B; Luo L; Fang Y
    Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis.
    Yan T; Hu P; Lv S; Ye M; Wu M; Fang H; Xiao B
    Cancer Chemother Pharmacol; 2024 Sep; 94(3):323-336. PubMed ID: 38824270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics.
    Chen H; Li C; Hu H; Zhang B
    BMC Mol Cell Biol; 2022 Aug; 23(1):38. PubMed ID: 35982414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
    Zhao W; Yun K
    Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
    Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
    Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.
    Wang J; Zhou F; Li Y; Li Q; Wu Z; Yu L; Yuan F; Liu J; Tian Y; Cao Y; Zhao Y; Zheng Y
    Cell Cycle; 2017; 16(24):2355-2365. PubMed ID: 29108461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tim-3 expression in glioma cells is associated with drug resistance.
    Zhang J; Zhu ZQ; Li YX; Zhuang QF; Lai Y; Li SF; Xu XB; Liu JM
    J Cancer Res Ther; 2019; 15(4):882-888. PubMed ID: 31436247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequent Nek1 overexpression in human gliomas.
    Zhu J; Cai Y; Liu P; Zhao W
    Biochem Biophys Res Commun; 2016 Aug; 476(4):522-527. PubMed ID: 27251576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
    Liang H; Chen Z; Sun L
    Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
    Lu XY; Cao K; Li QY; Yuan ZC; Lu PS
    J Int Med Res; 2012; 40(3):995-1004. PubMed ID: 22906272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
    Geng X; Zhang Y; Lin X; Zeng Z; Hu J; Hao L; Xu J; Wang X; Wang H; Li Q
    Cell Death Dis; 2022 Jul; 13(7):596. PubMed ID: 35817771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LncRNA-XIST interacts with
    Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
    Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
    Yin H; Cui X
    Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
    [No Abstract]   [Full Text] [Related]  

  • 60. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.